AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18603748 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 36
Study 16020594 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457
Study 16020594 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive strategy
Number of subjects: 2457
Study 12463857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Web‐based intervention
Number of subjects: 0
Study 12463857 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored Web‐based intervention
Number of subjects: 0
Study 12463857 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored paper-based intervention
Number of subjects: 0
Study 10634671 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-extensor training for 8 weeks
Number of subjects: 24
Study 10634671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training for 8 weeks
Number of subjects: 24
Study 10634671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 7589618 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 45
Study 7589618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 45
Study 7589618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 45
Study 7589618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 2066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal-parietal lesions
Number of subjects: 36
Study 2066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal lesions
Number of subjects: 36
Study 2066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lesions
Number of subjects: 36
Study 2066773 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36
Study 2066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock novels
Number of subjects: 36
Study 2066773 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 component
Number of subjects: 36
Study 6973990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone (200 mg)
Number of subjects: 59
Study 6973990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (1000 mg)
Number of subjects: 59
Study 6973990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31227028 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 or 50 mg/day for 2 months
Number of subjects: 0
Study 31227028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29210202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical activity (>8 hours/week)
Number of subjects: 422
Study 29210202 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (measured in MET hours)
Number of subjects: 422
Study 29210202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity physical activity
Number of subjects: 422
Study 29210202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical activity
Number of subjects: 422
Study 27428202 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) monotherapy
Number of subjects: 23
Study 27428202 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r) + 2 NRTIs
Number of subjects: 23
Study 23838727 — intervention group
Group type: EXPERIMENTAL
Intervention: P-ESDM
Number of subjects: 49
Study 23838727 — intervention group
Group type: COMPARATOR
Intervention: Community intervention
Number of subjects: 49
Study 23838727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 22139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous screw fixation
Number of subjects: 90
Study 22139387 — intervention group
Group type: COMPARATOR
Intervention: Plate and screws fixation
Number of subjects: 90
Study 20456070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Provocation Technique (PPT)
Number of subjects: 40
Study 20456070 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal inpatient treatment
Number of subjects: 40
Study 17276260 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical Tecnis Z9000 IOL
Number of subjects: 20
Study 17276260 — intervention group
Group type: COMPARATOR
Intervention: Spherical CeeOn Edge 911 IOL
Number of subjects: 20
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: DD genotype in male hypertensive patients
Number of subjects: 100
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele in male EH group
Number of subjects: 100
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP and PP in males with DD genotype
Number of subjects: 100
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP, DBP, and PP in female hypertensive patients
Number of subjects: 100
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution ratio of DD genotype in male EH group
Number of subjects: 100
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP in all three genotypes in male EH group
Number of subjects: 100
Study 16563249 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP, DBP, and PP between II and ID genotype in male EH group
Number of subjects: 100
Study 12172688 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 12172688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 12172688 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 12172688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10460188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sm‐153 PHYP/triamcinolone hexacetonide
Number of subjects: 60
Study 10460188 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid alone (triamcinolone hexacetonide)
Number of subjects: 60
Study 8552455 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvature of the visible contour
Number of subjects: 0
Study 8552455 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual angle of the visible arc
Number of subjects: 0
Study 2182423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential decision strategy
Number of subjects: 161
Study 2182423 — intervention group
Group type: COMPARATOR
Intervention: Fixed sample size approach
Number of subjects: 161
Study 91836 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention programme
Number of subjects: 375
Study 91836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study 30726268 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification mask
Number of subjects: 37
Study 30726268 — intervention group
Group type: COMPARATOR
Intervention: Non-heated humidification mask (placebo)
Number of subjects: 37
Study 29979445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg over 10 minutes before anesthesia induction and then 0.5 μg/kg/h until peritoneal closure)
Number of subjects: 0
Study 29979445 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 0
Study 26803950 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A injections (BoNT-A) in the parotid glands only
Number of subjects: 20
Study 26803950 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) on the parotid and posterior part of the submandibular glands
Number of subjects: 20
Study 25078309 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with ribavirin (group 1)
Number of subjects: 168
Study 25078309 — intervention group
Group type: COMPARATOR
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks without ribavirin (group 2)
Number of subjects: 168
Study 25078309 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks with ribavirin (group 3)
Number of subjects: 168
Study 25078309 — intervention group
Group type: COMPARATOR
Intervention: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks without ribavirin (group 4)
Number of subjects: 168
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels >10% at 3 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels >1-10% at 3 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels ≤1% at 3 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with >35% Philadelphia chromosome-positive metaphases at 3 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with ≤35% Philadelphia chromosome-positive metaphases at 3 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels >1% at 6 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL transcript levels ≤1% at 6 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with >0% Philadelphia chromosome-positive at 6 months
Number of subjects: 1303
Study 22446502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment with 0% Philadelphia chromosome-positive at 6 months
Number of subjects: 1303
Study 20129016 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A.
Number of subjects: 2737
Study 20129016 — intervention group
Group type: COMPARATOR
Intervention: Comparator ESA
Number of subjects: 2737
Study 17657694 — intervention group
Group type: EXPERIMENTAL
Intervention: HMD functioning without additional aids (Group 3)
Number of subjects: 45
Study 17657694 — intervention group
Group type: COMPARATOR
Intervention: HMD switched off (Group 2)
Number of subjects: 45
Study 17657694 — intervention group
Group type: COMPARATOR
Intervention: Conventional working aids (Group 1)
Number of subjects: 45
Study 15897212 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of screening questionnaire (SQ) results to GPs
Number of subjects: 1785
Study 12833999 — intervention group
Group type: EXPERIMENTAL
Intervention: Crataegus extract (3 times 30 drops for 8 weeks)
Number of subjects: 143
Study 12833999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 12833999 — intervention group
Group type: EXPERIMENTAL
Intervention: Crataegus extract
Number of subjects: 143
Study 11764109 — intervention group
Group type: COMPARATOR
Intervention: Group O: Prodigy resin‐based composite with OptiBond FL according to manufacturer's instructions
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Prolonged etching (60 s)
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: No etching of dentin
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Excessive drying after etching
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: Short rewetting after excessive drying
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E: Air drying and rewetting
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F: Blot drying
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G: Saliva contamination
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H: Application of primer and immediate drying
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Application of only primer
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group J: Application of only adhesive
Number of subjects: 96
Study 11764109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group K: No light curing of the adhesive before application of composite
Number of subjects: 96
Study 8857633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 11
Study 8857633 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 1284157 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (50 micrograms/kg over 5 min)
Number of subjects: 42
Study 1284157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. 10-ml bolus)
Number of subjects: 42
Study 1284157 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (5 mg over 5 min)
Number of subjects: 42
Study 2857523 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade therapy (BB) with metoprolol, titrated from 12.5 to 50 mg twice daily, final average dose 61 mg/day
Number of subjects: 50
Study 2857523 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (C) alone
Number of subjects: 50
Study 2857523 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade therapy (BB)
Number of subjects: 50
Study 31427046 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (675 mg month 1; placebo months 2 and 3)
Number of subjects: 838
Study 31427046 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (225 mg in episodic migraine and 675 mg in chronic migraine month 1; 225 mg months 2 and 3)
Number of subjects: 838
Study 31427046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 28415897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 39
Study 28415897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23766285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX with an ADS (T2)
Number of subjects: 26
Study 23766285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX without an ADS (T1)
Number of subjects: 26
Study 23766285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 26
Study 22958799 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus access to the online BREATH intervention
Number of subjects: 170
Study 22958799 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study 19651711 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month quality improvement intervention
Number of subjects: 418
Study 19651711 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 418
Study 17908184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion treatment
Number of subjects: 0
Study 17908184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) application
Number of subjects: 0
Study 17908184 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviscometer measurements
Number of subjects: 0
Study 17908184 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment for dryness and redness
Number of subjects: 0
Study 17908184 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneometer, Cutometer, Reviscometer, Evaporimeter and squamometry
Number of subjects: 0
Study 14732734 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral melatonin (2.5 mg) intake 1 hour before sleep for 3 weeks
Number of subjects: 16
Study 14732734 — intervention group
Group type: COMPARATOR
Intervention: Single dose of melatonin (2.5 mg)
Number of subjects: 16
Study 11843031 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced 2.8 MJ meal (23% fat)
Number of subjects: 13
Study 11843031 — intervention group
Group type: COMPARATOR
Intervention: Balanced low calorie 1.6 MJ meal (25% fat)
Number of subjects: 13
Study 11843031 — intervention group
Group type: COMPARATOR
Intervention: High fat 2.8 MJ meal (58% fat)
Number of subjects: 13
Study 9500750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-containing bar product
Number of subjects: 61
Study 7852749 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg per day
Number of subjects: 72
Study 7852749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg per day
Number of subjects: 72
Study 7852749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg retard twice a day
Number of subjects: 72
Study 7852749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 weeks prior to treatment)
Number of subjects: 72
Study 2789428 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous recombinant human EGF (hEGF) infusion (0.25-1.0 micrograms/kg)
Number of subjects: 0
Study 2789428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of pentagastrin
Number of subjects: 0
Study 2789428 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF)
Number of subjects: 0
Study 2789428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary feeding
Number of subjects: 0
Study 2789428 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 0
Study 329662 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenoxate
Number of subjects: 0
Study 329662 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31530611 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (4.4 g/day DHA orally)
Number of subjects: 52
Study 31530611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal fat supplement of vegetable oil)
Number of subjects: 52
Study 31530611 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 52
Study 27520366 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Process Improvement Intervention (OPII)
Number of subjects: 21
Study 27520366 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start condition
Number of subjects: 21
Study 27520366 — intervention group
Group type: COMPARATOR
Intervention: Early-start condition
Number of subjects: 21
Study 26466913 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus psychotherapy (pyridoxine hydrochloride 40 mg daily for 3 weeks + mindfulness-based cognitive therapy in eight 50 min sessions over 3 weeks)
Number of subjects: 86
Study 26466913 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (pyridoxine hydrochloride 40 mg daily for 3 weeks)
Number of subjects: 86
Study 25169035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing ice
Number of subjects: 0
Study 25169035 — intervention group
Group type: COMPARATOR
Intervention: Drinking tepid water
Number of subjects: 0
Study 22320999 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 126
Study 22320999 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 126
Study 20104970 — intervention group
Group type: EXPERIMENTAL
Intervention: 6th grade (or younger) cohort
Number of subjects: 3404
Study 20104970 — intervention group
Group type: COMPARATOR
Intervention: 8th grade (or older) cohort
Number of subjects: 3404
Study 17566394 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate (50/500 microg 2x/day)
Number of subjects: 6000
Study 15687411 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program of lifestyle modification
Number of subjects: 0
Study 15687411 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued patient-therapist contact (in person or by telephone, mail, or e-mail)
Number of subjects: 0
Study 15687411 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of physical activity and consumption of low-calorie, portion-controlled meals (including liquid meal replacements)
Number of subjects: 0
Study 15687411 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient content (e.g., low-fat vs. low-carbohydrate diets)
Number of subjects: 0
Study 15687411 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive weight loss control methods
Number of subjects: 0
Study 11278151 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 38
Study 11278151 — intervention group
Group type: COMPARATOR
Intervention: Other antipsychotic drugs (comparison group)
Number of subjects: 38
Study 11278151 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 38
Study 11278151 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 38
Study 10028794 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral dosage of 6 mg/kg of elemental iron (Group A)
Number of subjects: 55
Study 10028794 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oral dosage of 6 mg/kg of elemental iron, 3 days a week (Group B)
Number of subjects: 55
Study 7986970 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg t.d.s. with meals plus amoxycillin 750 mg t.d.s. with meals for 10 days
Number of subjects: 29
Study 7986970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg each evening for 6 weeks (for ulcer healing)
Number of subjects: 29
Study 7986970 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and amoxycillin therapy
Number of subjects: 29
Study 2927630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued positions (light cue at the same location)
Number of subjects: 0
Study 2927630 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-field non-coincident cue-target pairs
Number of subjects: 0
Study 2927630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-target asynchronies ranging from 0.2 to 1.5 sec
Number of subjects: 0
Study 2927630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues remote from the target within the same lateral or altitudinal visual hemifield
Number of subjects: 0
Study 2927630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues at 1 degree of visual angle from the midline and at 29 degrees from the cue
Number of subjects: 0
Study 113217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta blocker)
Number of subjects: 7
Study 113217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta-1 blocker)
Number of subjects: 7
Study 113217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7